1 ratings / 4 average

Endothelial Progenitor Cells as a Target for Therapy of Pulmonary Hypertension

Laszlo Farkas, MD1,2,3, and Martin R Kolb, MD, PhD1,2

Pulmonary hypertension (PH) is characterized by elevated pulmonary vascular pressure and resistance, which is associated with increased pressure in the pulmonary arterial and/or venous system [1]. Various conditions can underlie the development of PH, such as connective tissue disease, which leads to pulmonary arterial hypertension (PAH), but also myocardial or heart valve disease, resulting in pulmonary venous hypertension [1]. In a large subgroup of patients with PAH, the origin of the disease is unknown (defined as idiopathic PAH [IPAH]). Furthermore, a broad variety of chronic pulmonary diseases are associated with PH, including chronic obstructive pulmonary disease (COPD), interstitial lung disease, obstructive sleep apnea, and bronchopulmonary dysplasia [1]. Chronic thromboembolic disease is a major cause of PH, and is also included in the classification of PH [1]. 

Return to top


Pharmacotherapeutic Options for Pulmonary Arterial Hypertension
Myung H Park, MD
CML Pulmonary Hypertension
Congenital Heart Disease and Pulmonary Arterial Hypertension: Focus on Eisenmenger’s Syndrome
Julie Wacker and Maurice Beghetti, MD
CML Pulmonary Hypertension
Inflammatory Mechanisms 
in Pulmonary Hypertension
Ali Sadoughi, MD1,2, Yinzhong Zhang MD, PhD1, Edmund J Miller, PhD, FRSC1,3,4, and Arunabh Talwar, MD, FCC P1,2,3,4
CML Pulmonary Hypertension
Noninvasive Imaging in the Evaluation 
of Pulmonary Hypertension
Asghar A Fakhri, MD1, Vikas K Rathi, MD, FACC2, Rachel Hughes-Doichev, MD, FASE1, and Raymond L Benza, MD1
CML Pulmonary Hypertension
Sickle Cell Disease-Associated Pulmonary Hypertension: the Effect of Anemia and High Cardiac Output
Shoaib Alam, MD, and Gregory J Kato, MD
CML Pulmonary Hypertension